

Abstract

The invention is directed to use of fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or “organ-like” tissue. A preferred embodiment is a plasma-derived fibrin matrix containing cells.